We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Allopurinol in Acute Gout

This study has been withdrawn prior to enrollment.
(because of a lack of funding)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01775098
First Posted: January 24, 2013
Last Update Posted: May 11, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Artur de Brum-Fernandes, Université de Sherbrooke
January 21, 2013
January 24, 2013
May 11, 2017
Not Provided
December 2012   (Final data collection date for primary outcome measure)
Duration of the gout crises [ Time Frame: First 7 days after visit ]
Presence of inflammatory signs
Same as current
Complete list of historical versions of study NCT01775098 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Allopurinol in Acute Gout
Allopurinol in Acute Gout The Title Will Not be Change as the Study as Been Closed.
The objectives of the present study are to determine if starting treatement of hyperuricemia with allopurinol during an acute gout crises has an impact on the duration or the severity of the crises
Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Gout
Drug: allopurinol
No arms will not be change as the study as been closed.
  • Experimental: Allopurinol
    treatment with allopurinol
    Intervention: Drug: allopurinol
  • Placebo Comparator: placebo
    placebo comparator
    Intervention: Drug: allopurinol
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
February 2013
December 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

More than 18 years old Able to sign informed consent Indication of long-term treatment with allopurinol Acute gout crisis

Exclusion Criteria:

Les than 18 years-old Unable to consent Contra-indication to allopurinol

Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01775098
Allopurinol in acute gout
Yes
Not Provided
Not Provided
Artur de Brum-Fernandes, Université de Sherbrooke
Université de Sherbrooke
Not Provided
Not Provided
Université de Sherbrooke
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP